RFA-DK-23-019: Integration of Novel Measures for Improved Classification of Type 2 Diabetes (U01, Clinical Trials Not Allowed)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2023.
National Institutes of Health offered grants of up to $500,000 to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on October 26, 2023.
From the official notice on Grants.gov, last changed May 31, 2023. Checked November 7, 2026.
- Award ceiling$500,000
- Cost sharingNot required
- Funding typeCooperative Agreement
About this NIH notice
- Activity codeU01
- Clinical trialsNot allowed
- Funded byNIDDK
- Median yearly award$784,477
- Typical project length5 years
- U01, Research Project Cooperative Agreement. Like an R01, but NIH staff are substantially involved in the work. Other open U01 notices.
Projects funded under RFA-DK-23-019 were run by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK, 4 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-DK-23-019 in the NIH Guide.
Key dates
| Posted | May 31, 2023 |
|---|---|
| Deadline | October 26, 2023 |
| Archived by Grants.gov | December 1, 2023 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Is this a realistic fit?
- Projects NIH funded under this notice had a median yearly award of $784,477; it allows up to $500,000 per award.
- Most of the program's money (70% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
The purpose of this NOFO is to create a consortium to bring together investigative teams for integration of multiple data types, including markers of organ or tissue function, into analysis approaches for stratifying individuals with type 2 diabetes (T2D) and developing more precise definitions of disease. The ultimate goal of this effort will be to 1) develop a broadly applicable framework for identifying subtypes of T2D; and 2) increase understanding ofthe physiologic drivers of T2D subtypes to guide development of more effective precision interventions.
Funded under RFA-DK-23-019 so far
NIH funded 4 projects under RFA-DK-23-019 in fiscal 2024 to 2026, at 3 institutions. The median yearly award was $784,477.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| GEneration and assessment of Multi-omic informed Subtypes of Type 2 Diabetes (GEMS-T2D) | Massachusetts General Hospital | 2026 | $779,939 |
| Longitudinal omics-based trajectories of type 2 diabetes subtypes: the T2D Heterogeneity Consortium | Massachusetts General Hospital | 2026 | $811,521 |
| Metabolomic and genomic expansion of type 2 diabetes subtyping across populations | Wake Forest University Health Sciences | 2026 | $663,861 |
| Improving disease subtyping and physiological characterization of adult-onset diabetes in electronic health records | Vanderbilt University Medical Center | 2026 | $867,269 |
Who has won Diabetes, Digestive, and Kidney Diseases Extramural Research grants before
From fiscal 2021 to 2025, Diabetes, Digestive, and Kidney Diseases Extramural Research (93.847) awarded $9.6 billion across 7,877 grant awards, an average of $1.2 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Regents of the University of Michigan | Michigan | 273 | $345 million |
| The Trustees of the University of Pennsylvania | Pennsylvania | 187 | $272 million |
| University of Pittsburgh - of the Commonwealth System of Higher Education | Pennsylvania | 209 | $238 million |
| The Washington University | Missouri | 187 | $227 million |
| The Regents of the University of California, San Francisco | California | 176 | $208 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-DK-23-019 still open?
No. It closed on October 26, 2023.
Who can apply for Integration of Novel Measures for Improved Classification of Type 2 Diabetes (U01, Clinical Trials Not Allowed)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Integration of Novel Measures for Improved Classification of Type 2 Diabetes (U01, Clinical Trials Not Allowed)?
Closed October 26, 2023. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $500,000 each.
Who has been funded under RFA-DK-23-019?
NIH RePORTER lists 4 projects funded under RFA-DK-23-019 in fiscal 2024 to 2026, at 3 institutions. The most were at Massachusetts General Hospital, Wake Forest University Health Sciences, Vanderbilt University Medical Center.
Who has won Diabetes, Digestive, and Kidney Diseases Extramural Research grants before?
The largest recipients over five fiscal years were Regents of the University of Michigan, The Trustees of the University of Pennsylvania, University of Pittsburgh - of the Commonwealth System of Higher Education. The program made 7,877 awards worth $9.6 billion in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Single Source for the Continuation of the Physiology of the Weight Reduced State (POWERS) Study (U01- Clinical Trials Required)
- Canine Cancer Immunotherapy Network (K9CIN; U01 Clinical Trial Not Allowed)
- Opportunities for Collaborative Research with the NIH Intramural Research Program (U01 Clinical Trial Optional)